$10 Billion Deal, page-87

Are the distributors of the anti-retroviral drugs seeing you as a disruptor to their business?  Because obviously they have an ongoing business of selling these things that people take once a day, you potentially disrupt that.  Are they seeing you as that or as a potential partner?  Are you in fact looking to set up an auction between them to bid for your IP?

Well that’s the ideal situation, having more than one buyer for your product, set that up.  I think the industry the number of major pharmaceutical companies, big pharma, that are in the anti-retroviral drug space, they are all very interested in this area and some of them are getting a bit long in the tooth.  They’ve got quite big bank charges to protect in terms of the HIV space, they’ve got their clinicians, they’ve got their sales and marketing team and everything out there, they get a fair whack of their revenue from these products.  They’re coming to the cliff, the potential for more generics coming along and then losing that share is quite a real prospect.